Clinical Trial

Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment

Study acronym: MCI-MCT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2025 (before its estimated July 3, 2025 completion). Its status may not reflect the trial's current state.
Summary
Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Trial Details
NCT Number NCT06951932
Lead Sponsor Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Collaborators: Dr. Schär AG / SPA
Conditions Mild Cognitive Impairment (MCI)
Enrollment 120 participants
Start Date 2024-07-03
Primary Completion 2025-07-03 (estimated)
Study Completion 2025-11-03 (estimated)
Updated on ClinicalTrials.gov 2025-05-04